313 related articles for article (PubMed ID: 38006751)
1. Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds.
Elnosary ME; Shreadah MA; Ashour ML; Nabil-Adam A
Int Immunopharmacol; 2024 Jan; 126():111072. PubMed ID: 38006751
[TBL] [Abstract][Full Text] [Related]
2. The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients.
Hariharan A; Hakeem AR; Radhakrishnan S; Reddy MS; Rela M
Inflammopharmacology; 2021 Feb; 29(1):91-100. PubMed ID: 33159646
[TBL] [Abstract][Full Text] [Related]
3. Proinflammatory Cytokine Profiles in Both Mild Symptomatic and Asymptomatic SARS-CoV-2-Infected Egyptian Individuals and a Proposed Relationship to Post-COVID-19 Sequela.
Bahgat MM; Nadeem R; Nasraa MH; Amer K; Hassan WA; ELGarhy FM; Reda S; Abd-Elshafy DN
Viral Immunol; 2023 Nov; 36(9):600-609. PubMed ID: 37831918
[TBL] [Abstract][Full Text] [Related]
4. Profiling Inflammatory Cytokines in a Cohort Study of Egyptian Patients with COVID-19 Infection.
Gharib AF; Askary AE; Hassan AF; Ismail KA; Hagag HM; Khalifa AM; Sami R; Amin HS; Youssef IH
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107645
[TBL] [Abstract][Full Text] [Related]
5. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
6. NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
Samsonia M; Kandelaki M; Baratashvili N; Gvaramia L
Georgian Med News; 2023 Feb; (335):111-118. PubMed ID: 37042600
[TBL] [Abstract][Full Text] [Related]
7. Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2.
Su CM; Wang L; Yoo D
Sci Rep; 2021 Jun; 11(1):13464. PubMed ID: 34188167
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
9. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK/NF-κB pathway.
Tirunavalli SK; Gourishetti K; Kotipalli RSS; Kuncha M; Kathirvel M; Kaur R; Jerald MK; Sistla R; Andugulapati SB
Phytomedicine; 2021 Nov; 92():153729. PubMed ID: 34517257
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection.
Bozorgmehr N; Mashhouri S; Perez Rosero E; Xu L; Shahbaz S; Sligl W; Osman M; Kutsogiannis DJ; MacIntyre E; O'Neil CR; Elahi S
mBio; 2021 May; 12(3):. PubMed ID: 33947753
[TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 Severity Shifts the Cytokine Milieu Toward a Proinflammatory State in Egyptian Patients: A Cross-Sectional Study.
Salem ML; Eltoukhy MM; Shalaby RE; Okasha KM; El-Shanshoury MR; Attia MA; Hantera MS; Hilal A; Eid MA
J Interferon Cytokine Res; 2023 Jun; 43(6):257-268. PubMed ID: 37252793
[TBL] [Abstract][Full Text] [Related]
14. Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients.
Mortaz E; Tabarsi P; Jamaati H; Dalil Roofchayee N; Dezfuli NK; Hashemian SM; Moniri A; Marjani M; Malekmohammad M; Mansouri D; Varahram M; Folkerts G; Adcock IM
Front Immunol; 2021; 12():592727. PubMed ID: 33968010
[TBL] [Abstract][Full Text] [Related]
15. Immunological and biochemical biomarker alterations among SARS-COV-2 patients with varying disease phenotypes in Uganda.
Kato CD; Nsubuga J; Niyonzima N; Kitibwa A; Matovu E; Othieno E; Ssebugere P; Tumwine AA; Namayanja M
BMC Infect Dis; 2023 Dec; 23(1):857. PubMed ID: 38057707
[TBL] [Abstract][Full Text] [Related]
16. Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection.
Elizagaray ML; Mazitelli I; Pontoriero A; Baumeister E; Docena G; Raimondi C; Correger E; Rumbo M
Biomed J; 2023 Feb; 46(1):81-92. PubMed ID: 35948250
[TBL] [Abstract][Full Text] [Related]
17. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
18. Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets.
Zhang J; Li Q; Cruz Cosme RS; Gerzanich V; Tang Q; Simard JM; Zhao RY
mBio; 2021 Feb; 13(1):e0016922. PubMed ID: 35164548
[TBL] [Abstract][Full Text] [Related]
19. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients.
Gomes SMR; Brito ACS; Manfro WFP; Ribeiro-Alves M; Ribeiro RSA; da Cal MS; Lisboa VDC; Abreu DPB; Castilho LDR; Porto LCMS; Mafort TT; Lopes AJ; da Silva SAG; Dutra PML; Rodrigues LS
PLoS One; 2023; 18(4):e0283983. PubMed ID: 37018291
[TBL] [Abstract][Full Text] [Related]
20. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19.
Attiq A; Yao LJ; Afzal S; Khan MA
Int Immunopharmacol; 2021 Dec; 101(Pt B):108255. PubMed ID: 34688149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
